期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

替格瑞洛相关呼吸困难的机制与诊治 被引量：7

Mechanisms,Diagnosis and Treatment of Ticagrelor-related Dyspnea
下载PDF
导出
摘要 替格瑞洛是一种能可逆性结合血小板P2Y_(12)受体的新型口服抗血小板聚集药。与氯吡格雷(一种不可逆阻断P2Y_(12)受体的抗血小板药)相比,它具有更好的疗效和相似的安全性。血小板上P2Y_(12)受体介导ADP引起的血小板凝聚,替格瑞洛及其活性代谢产物通过可逆性阻断P2Y_(12)受体从而抑制血小板聚集反应;但是,替格瑞洛可以引发呼吸困难,有时限制了其临床应用。现对替格瑞洛相关呼吸困难的发生率、发生机制、诊断以及处理进行综述。 Ticagrelor is a novel oral antiplatelet drug, which can reversibly bind the platelet P2Y12 receptor. Compared with clopidogrel ,a traditionally used irreversible P2Y12 receptor blocking antiplatelet drug, ticagrelor displayed better efficacy and safety. However, ticagrelor may cause dyspnea, which sometimes limits its clinical application. This article reviews the mechanisms, diagnosis and treatment of ticagrelor-related dyspnea.
作者 盛兆雪 赵汉军
机构地区 北京协和医学院中国医学科学院国家心血管病中心阜外医院心血管内科
出处 《心血管病学进展》 CAS 2016年第5期508-511,共4页 Advances in Cardiovascular Diseases
基金 中央级公益性科研院所基本科研业务费专项资金/院所青年科学基金(2012-F25)
关键词 替格瑞洛 呼吸困难 腺苷 Ticagrelor Dyspnea Adenosine
分类号 R973 [医药卫生—药品]
  • 相关文献

参考文献31

  • 1Wallentin L, Becker RC,Budaj A,et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes[J]. N Engl J Med,2009,361 (11 ) :1045-1057.
  • 2Cannon CP, Husted S, Han4nglon RA, et al. Safety, tolerability, and initial effica- cy of AZD6140,the first reversible oral adenosine diphosphate receptor antago- nist,compared with clopidogrel,in patients with non-ST-segment elevation acute coronary syndrome :primary results of the DISPERSE-2 trial[ J]. J Am Coil Car- dio1,2007,50(19) :1844-1851.
  • 3Husted S,Emanuelsson H, Heptinstall S, et al. Phmxnacodyuamics, phannacoki- netics,aud safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with athemsclerosis : a double-blind comparison to clopidogrel with as- pirin[J]. Eur Heart J,2006,27(9) :1038-1047.
  • 4Gurbel PA, Bliden KP, Buffer K, et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiptatelet effects of ticagrelor versus clopi- dogrel in patients with stable coronary artery disease: The ONSET/OFFSET study [ J ]. Circulation, 2009,120 ( 25 ) : 2577 -2585.
  • 5Gurbel PA, Bliden KP, Butler K, et al. Response to ticagrelor in clopidogrel non- responders and responders and effect of switching therapies: The RESPOND study[ J ]. Circulation ,2010,121 ( 10 ) : 1188-1199.
  • 6Caldeira D, Pinto FJ, Ferreira JJ. Dyspnea and reversibility profile of P2YI2 an- tagonists:systematic review of new antiplatelet drugs [ J ]. Am J Cardiovasc Drugs,2014,14(4) :303-311.
  • 7邵春丽,颜红兵,乔树宾,唐熠达,慕朝伟,赵汉军,华倚虹,卿平.替格瑞洛相关呼吸困难的调查分析[J].中国介入心脏病学杂志,2015,23(2):85-88. 被引量：23
  • 8Storey RF,Bliden KP, Patil SB, et ah Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease re- ceiving ticagrelor,clopidogrel, or placebo in the ONSET/OFFSET study [ J ]. J Am Coil Cardio1,2010,56 ( 3 ) : 185-193.
  • 9Storey RF, Becker RC, Harrington RA,et ah Pulmonary function in patients with acute coronary syndrome treated with ticagrelor or clopidogrel ( tiom the Platelet Inhibition and Patient Outcomes [ PLATO ] pulmonary function substudy ) [J].Am J Cardiol,2011,108( 11 ) :1542-1546.
  • 10Burki NK, Dale W J, Lee LY. Intravenous adenosine and dyspnea in humans [J]. J Appl Physiol (1985) ,2005,98( 1 ) :180-185.

二级参考文献33

  • 1Storey RF, Angiolillo D J, Patil SB, et al. Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (Platelet Inhibition and Patient Outcomes ) PLATELET substudy. J Am Coll Cardiol,2010,56 : 1456-1462.
  • 2Wallentin L, Becket RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med ,2009,361 : 1045-1057.
  • 3Parodi G, Storey RF. Dyspnoea management in acute coronary syndrome patients treated with ticagrelor. Eur Heart J Acute Cardiovasc Care,2014. [Epub ahead of print].
  • 4Husted S, Emanuelsson H, Heptinstall S, et al. Pharmacodynarnics, pharmacokinetics, and safety of the oral reversible P2Yn antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to elopidogrel with aspirin. Eur Heart J,2006,27 : 1038-1047.
  • 5Cannon CP, Husted S, Harrington RA, et al. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. J Am Coll Cardiot,2007,50: 1844-1851.
  • 6Storey RF, Bliden KP, Patil SB, et al. Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor, clopidogrel, or placebo in the ONSET/OFFSET study. J Am Coll Cardiol,2010, 56 : 185-193.
  • 7Storey RF, Becker RC, Harrington RA, et al. Pulmonary function in patients with acute coronary syndrome treated with ticagrelor or clopidogrel (from the Platelet Inhibition and Patient Outcomes [ PLATO ] pulmonary function substudy ). Am J Cardiol, 2011, 108 : 1542-1546.
  • 8Gaubert M, Laine M, Richard T, et al. Effect of ticagrelor-related dyspnea on compliance with therapy in acute coronary syndrome patients. Int J Cardiol,2014,15,173 : 120-121.
  • 9Bonello L, Laine M, Kipson N, et al. Ticagrelor increases adenosine plasma concentration in patients with an acute coronary syndrome. J Am Coll Cardio1,2014,63:872-877.
  • 10Headrick JP, Lasley RD. Adenosine receptors and repeffusion injury of the heart. Handb Exp Pharmacol,2009,193 : 189-214.

共引文献41

同被引文献59

二级引证文献19

心血管病学进展
2016年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部